

10/581178

|   |               |                            |
|---|---------------|----------------------------|
| "Express Mail" mailing label number   | EV 39312      | AP2006 PTO 31 MAY 2006     |
| Date of Deposit   | 5/31/06       |                            |
| I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. |               |                            |
| Printed Name  | Don's N Jones | Signature <i>Don Jones</i> |

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Marta Garcia De La Torre  
For: OPIOID RECEPTOR ANTAGONISTS  
Docket No.: X-16440

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

*John C. Demeter*

John C. Demeter  
Attorney for Applicant(s)  
Registration No. 30,167  
Phone: 317-276-3785

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

April 11, 2006

|  |   |                                |
|--|---|--------------------------------|
| FORM PTO 1449 (modified)<br><br>INFORMATION DISCLOSURE CITATION<br>IN AN APPLICATION | Atty. Docket No.<br>X-16440                 | Serial No.<br><b>10/581178</b> |
|  | First Applicant<br>Marta Garcia De La Torre |                                |
|  | Filing Date                                 | Group                          |

**U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number<br>Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Pages<br>or Relevant Figures<br>Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
|                    | AA                    | US  |                                |  |   |
|                    | AB                    | US  |                                |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> -Number <sup>4</sup> -<br>Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|--|--------------------------------|---|---|----------------|
|                    | BA                    | WO 2004/026305   | April 1, 2004                  | Eli Lilly and Company                                 |   |                |
|                    | BB                    | WO 02/38544  | May 16, 2002                   | Eli Lilly and Company                                 |   |                |
|                    | BC                    | WO 2004/080968   | September 23, 2004             | Eli Lilly and Company                                 |   |                |
|                    | BD                    | WO 2004/080996   | September 23, 2004             | Eli Lilly and Company                                 |   |                |
|                    | BE                    | WO 00/40560  | July 13, 2000                  | Fujisawa Pharmaceutical Co. Ltd.                      |   |                |
|                    | BF                    | WO 98/09625  | March 12, 1998                 | Eli Lilly and Company                                 |   |                |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published. | T <sup>6</sup> |
|--------------------|-----------------------|--|----------------|
|                    | CA                    |  |                |
|                    | CB                    |  |                |
|                    | CC                    |  |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.